lilly cease and desist tirzepatide Eli Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves eli lilly tirzepatide cease and

holds a market share of 72.3%, due to widespread use of GLP-1 receptor agonists such as Ozempic, Wegovy, and Trulicity, along with favorable reimbursement policies and increasing focus on chronic disease management The presence of leading pharmaceutical companies such as Novo Nordisk and Eli Lilly, combined with high awareness among healthcare providers and patients, contributes to the regions leadership In addition, the ongoing clinical trials and FDA approvals for expanded indications of GLP-1 therapies continue to stimulate growth and investment across North America Asia-Pacific is Projected to Register the Highest CAGR in the GLP-1 Analogues Market Asia-Pacific is expected to experience the highest compound annual growth rate, driven by the rising incidence of type 2 diabetes and obesity, growing urbanization, and dietary shifts across developing economies Countries such as China, India, and Japan are becoming key growth engines due to large diabetic populations, increasing healthcare spending, and efforts to improve chronic disease management Japans advanced healthcare system and regulatory support for innovative treatments make it a significant market for GLP-1 drugs, while China's expanding middle class and government initiatives on diabetes care are boosting demand Indias growing awareness of lifestyle diseases, coupled with rising accessibility to branded and biosimilar GLP-1 therapies, is contributing to regional expansion

The honest summary: Retatrutide probably does produce modestly greater weight loss than tirzepatide at maximum doses, potentially in the range of 36 percentage points of body weight

Sankar Bhattacharyya, Sidho Kanho Birsha University, India

10.1016/j.phrs.2019.104554 32

However, the direct relationship between semaglutide and GERD is not well-established

Published in the August 2025 issue of the journal Obesity , Long-acting PYY3-36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies, explores preclinical rat and phase 1 and 2 human trials assessing the efficacy and tolerability of PYY and semaglutide